Compare State Street SPDR S&P Biotech ETF (XBI) vs Consumer Discretionary Select Sector SPDR Fund (XLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR S&P Biotech ETF vs Consumer Discretionary Select Sector SPDR Fund — how do they compare? State Street SPDR S&P Biotech ETF trades at $153.85 (market cap $10.11B), while Consumer Discretionary Select Sector SPDR Fund trades at $112.69 (market cap $21.89B). The key difference: Consumer Discretionary Select Sector SPDR Fund is far larger — about 2.2× State Street SPDR S&P Biotech ETF's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Consumer Discretionary Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold State Street SPDR S&P Biotech ETF for 38 Days and Consumer Discretionary Select Sector SPDR Fund for 114 Days on average.
| XBI | XLY | |
|---|---|---|
Market Cap | $10.11B | $21.89B |
Volume | 12,903,266 | 5,690,342 |
Sector | Broad Market / Factor | — |
52-Week High | $169.55 | $124.52 |
52-Week Low | $104.99 | $105.64 |
Typical Hold Time | 38 Days | 114 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
XLY trades at $112.85, up 1.34% with a bullish technical signal despite mixed momentum indicators. The ETF shows strong analyst consensus with 100% buy ratings but faces fundamental data gaps. Recent news highlights consumer discretionary sector challenges, with XLY underperforming staples by 13% year-to-date amid inflation pressures and selective consumer spending trends.
Outlook remains cautiously optimistic given analyst support, but persistent underperformance versus the S&P 500 and inflation risks warrant monitoring. The 'funflation' trend and potential holiday sales growth offer upside catalysts, though sector volatility and Tesla's weighting drag present near-term headwinds for discretionary exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →About Consumer Discretionary Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.
Read more on XLY →
